Atlas Trials

A Pivotal Study to Evaluate the Bio-equivalence of the Tapentadol Extended-Release (ER) Tamper-resistant Formulation (TRF) Tablet to the Current Tapentadol ER Prolonged-release 2 (PR2) Tablet

Clinical trial NCT01900587 · COMPLETED

Trial details

NCT number
NCT01900587
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Healthy
Start date
2010-07-01
Primary completion
2010-08-01
Enrollment
64

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.